DESIGN, FORMULATION AND EVALUATION OF ANTIPSORIATIC TRANSDERMAL FILM FORMING GELS LOADED WITH TRIAMCINOLONE
Boggavarapu Nagalakshmi1
Department of Pharmaceutics, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India
Manasa E
Department of Pharmacognosy & Phytochemistry, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India
Sandhya K
Department of Pharmaceutical Chemistry, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore- 524346, Andhra Pradesh, India
Divya
Department of Pharmaceutics, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India
Triamcinolone acetonide (TCA), a potent steroid that is used to treat various inflammatory and autoimmune conditions, faces challenges when it comes to maintaining consistent therapeutic levels through the use of conventional dosage forms. As part of this study, triamcinolone-loaded transdermal films were developed and evaluated with the intent of improving drug delivery, increasing patient compliance, and reducing systemic side effects. A solvent casting method was used to prepare the transdermal films, which were formulated using a combination of hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA) in different concentrations to optimize their properties. It was determined that triamcinolone is compatible with the selected polymers after performing pre-formulation studies. It was assessed that the prepared films met all of the pharmacopoeial standards for their physicochemical properties, including thickness, tensile strength, folding endurance, and drug content uniformity, all of which met pharmacopoeial standards. As a means of simulating skin conditions, in vitro studies of drug release were performed using Franz diffusion cells in phosphate buffer (pH 7.4) at 32°C to mimic the conditions on the skin. As a result of this study, we have developed triamcinolone-loaded transdermal films that may provide an effective and sustained delivery method of triamcinolone for the treatment of inflammatory and autoimmune diseases, potentially improving therapeutic outcomes and patient adhesion
14 , 1 , 2024
34 - 42